Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 12/20 | 0.54 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | BRD1 | O95696 | 1/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8557904 | 0.78 | PKM (0.73) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL26750468 | 0.77 | DAGLA (0.44) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL10154341 | 0.76 | PKM (0.66) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL25521770 | 0.75 | PKM (0.46) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL4521621 | 0.74 | PKM (0.58) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL8557528 | 0.73 | PKM (0.71) | PKMCYP2D6TRIM24BRD1BRPF1 | |
| SCHEMBL8487793 | 0.73 | DAGLA (0.59) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL2243703 | 0.72 | PKM (0.53) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL22062309 | 0.72 | PKM (0.53) | DAGLAABHD6PKMCYP2D6CYP3A4 | |
| SCHEMBL25522397 | 0.72 | PKM (0.50) | DAGLAABHD6PKMCYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3606533-B1 | PROCESS FOR PREPARATION OF SULFONYL CARBAMATE BILE ACID DERIVATIVES | ENANTA PHARM INC (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-10961272-B2 | Process for preparation of sulfonyl carbamate bile acid derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200317717-A1 | PROCESS FOR PREPARATION OF SULFONYL CARBAMATE BILE ACID DERIVATIVES | ENANTA PHARM INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10676500-B2 | Process for preparation of sulfonyl carbamate bile acid derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961272-B2 | Process for preparation of sulfonyl carbamate bile acid derivatives | GPBAR1, NR1H4, SLC10A1 | DAGLA 1217/4885ABHD6 720/4885PKM 2038/4885 |
| US-10676500-B2 | Process for preparation of sulfonyl carbamate bile acid derivatives | GPBAR1, NR1H4, SLC10A1 | DAGLA 1359/4885ABHD6 776/4885PKM 1988/4885 |
| US-20200317717-A1 | PROCESS FOR PREPARATION OF SULFONYL CARBAMATE BILE ACID DERIVATIVES | GPBAR1, NR1H4, SLC10A1 | DAGLA 1217/4885ABHD6 720/4885PKM 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.